vemurafenib
Selected indexed studies
- Vemurafenib. (Recent Results Cancer Res, 2018) [PMID:30069761]
- Vemurafenib. (Recent Results Cancer Res, 2014) [PMID:24756795]
- Vemurafenib-induced granulomatous hepatitis. (Hepatology, 2017) [PMID:27335285]
_Worker-drafted node — pending editorial review._
Connections
vemurafenib is a side effect of
Sources
- Vemurafenib. (2018) pubmed
- Vemurafenib. (2014) pubmed
- Vemurafenib-induced granulomatous hepatitis. (2017) pubmed
- Vemurafenib in melanoma. (2013) pubmed
- Vemurafenib. (2011) pubmed
- Clinical Pharmacokinetics of Vemurafenib. (2017) pubmed
- Vemurafenib: in unresectable or metastatic melanoma. (2012) pubmed
- Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. (2014) pubmed
- Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. (2012) pubmed
- Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. (2022) pubmed